Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma (Q34576803)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Michelle A Fanale

1

object named as

Michelle A Fanale

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Anas Younes

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

67

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

333-350

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumo

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAFF and the regulation of B cell survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

To die or not to die--the quest of the TRAIL receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAFF AND APRIL: a tutorial on B cell survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The TNF family members BAFF and APRIL: the growing complexity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD40-CD40 ligand

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel immune-based treatment strategies for chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD2 signaling in T cells involves tyrosine phosphorylation and activation of the Tec family kinase, EMT/ITK/TSK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The uncertain glory of APRIL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The B7 and CD28 receptor families

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD30 ligand in lymphoma patients with CD30+ tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor-mediated choreography of life and death.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B7-mediated costimulation and the immune response

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biology of VEGF and its receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic monoclonal antibodies in oncology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humanized antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and proliferation factors of normal and malignant plasma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From angiogenesis to lymphangiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mouse CD20 expression and function

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dynamics of life and death of malignant lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody conjugates and therapeutic strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Death receptors: signaling and modulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biology of CD20 and its potential as a target for mAb therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17335294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200767030-00002

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34576803&oldid=2196815417"